<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">KÜMMEL, SHERKO</style></author><author><style face="normal" font="default" size="100%">EGGEMANN, HOLM</style></author><author><style face="normal" font="default" size="100%">LÜFTNER, DIANA</style></author><author><style face="normal" font="default" size="100%">THOMAS, ANKE</style></author><author><style face="normal" font="default" size="100%">JESCHKE, SOPHIA</style></author><author><style face="normal" font="default" size="100%">ZERFEL, NADINE</style></author><author><style face="normal" font="default" size="100%">HEILMANN, VOLKER</style></author><author><style face="normal" font="default" size="100%">EMONS, GÜNTER</style></author><author><style face="normal" font="default" size="100%">ZEISER, TOBIAS</style></author><author><style face="normal" font="default" size="100%">ULM, KURT</style></author><author><style face="normal" font="default" size="100%">KOBL, MICHAEL</style></author><author><style face="normal" font="default" size="100%">KORLACH, SUSANNE</style></author><author><style face="normal" font="default" size="100%">SCHMID, PETER</style></author><author><style face="normal" font="default" size="100%">SEHOULI, JALID</style></author><author><style face="normal" font="default" size="100%">ELLING, DIRK</style></author><author><style face="normal" font="default" size="100%">BLOHMER, JENS-UWE</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Changes in the Circulating Plasma Levels of VEGF and VEGF-D after Adjuvant Chemotherapy in Patients with Breast Cancer and 1 to 3 Positive Lymph Nodes</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1719-1726</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><issue><style face="normal" font="default" size="100%">2C</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The goal of the present study was to investigate the changes in concentration of the important lymph-angiogenesis factors vascular endothelium-derived growth factor (VEGF) and VEGF-D under adjuvant chemotherapy. Materials and Methods: The blood plasma of a total of 142 patients with breast carcinoma and with 1 to 3 affected lymph nodes was investigated, using the quantitative sandwich enzyme immunoassay technique, prior to and following chemotherapy, within the framework of a randomized phase III study: the patients received either conventional or dose-intensified chemotherapy. Results: In general, there was a significant reduction in VEGF levels after chemotherapy only in patients with large tumors (T3) (p=0.043). There was also an almost significant reduction in patients with an overexpression of c-erbB-2 (Dako Score +3, p=0.052). In contrast, the clearest reduction in VEGF-D occurred in patients with a positive hormone receptor status (p=0.04) or in patients with a low expression of c-erbB-2 (Dako Score +1, p=0.05). A significant effect of chemotherapy on VEGF-D was determined only in patients who had a baseline level that was above the normal (conventionel treatment p=0.005; dose-intensified treatment p=0.004). Conclusion: Both VEGF and VEGF-D levels changed after chemotherapy, depending on the patient and tumor characteristics. With respect to changes in the plasma levels of VEGF and VEGF-D, there were no significant differences between dose-intensified and conventional chemotherapy. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>